hADM vs PDLLA
This page places verifiable specifications side by side. It does not rank materials, score them, or recommend one over another.
Comparison
What is the difference between an ECM-derived matrix and a synthetic collagen biostimulator?
These two sit on opposite sides of the central distinction in this atlas. hADM is donated human dermis with the cells removed, so the extracellular matrix itself is what is placed in the tissue. PDLLA is a synthetic polymer that supplies no matrix; the literature describes it as provoking a foreign-body response after which the host deposits its own. They also sit in different bodies of law: donated tissue is governed by tissue legislation, while the synthetic polymer follows the medical device route.
| Aspect | hADM (Human acellular dermal matrix) | PDLLA (Poly-D,L-lactic acid) | Basis |
|---|---|---|---|
| Origin | Donated human dermis, decellularised | Synthetic polymer | — |
| What is placed in the tissue | Extracellular matrix scaffold | Polymer particles; no matrix is supplied | — |
| Sequence described in the literature | Host cell repopulation of the scaffold and constructive remodelling | Foreign-body response to the particle, fibroblast activity, matrix deposition by the host | — |
| Persistence question asked | Whether the scaffold is remodelled and integrated | How long the particle remains before hydrolysis | — |
| Regulatory identity — Korea | Not a cosmetic, device or drug — donated tissue under the Act on Safety and Management of Human Tissue | Medical device, tissue-repair biomaterial route | Legal text |
| Regulatory identity — United States | Human cells, tissues and cellular and tissue-based products under 21 CFR Part 1271 | Not established from public sources | Legal text |
| Variability that has to be managed | Donor screening and lot-to-lot variation; decellularisation and sterilisation methods differ between manufacturers | Particle specifications are not standardised between manufacturers | — |
| Randomised trials cited on this site | PMID 41381953, PMID 41828422 — micronised and particulate forms, 2026 | PMID 39178357 — evaluator-blinded multicentre comparison | — |
Supply versus provoke
This is the distinction the rest of the atlas is organised around. One family of materials places extracellular matrix into the dermis. The other places something the body reacts to, and the matrix that appears afterwards is the host’s own. Both routes end with matrix in the tissue, which is why they are often discussed together, but the starting move is not the same and the questions worth asking about each are different.
The questions are not interchangeable
For a scaffold, the useful question is whether host cells move in and remodel it. For a particulate polymer, the useful question is how long the particle stays before it hydrolyses. Asking about “duration” of both as if it were one variable produces an answer that fits neither.
Two materials, two bodies of law
The regulatory rows here are not a matter of tier or class within one system — they are different systems. Donated tissue is handled under tissue legislation in Korea and under the human cells and tissues framework in the United States. The synthetic polymer follows the device route. Anyone planning a filing, an import, or a market entry needs to know which of the two they are holding before anything else.
Limitations & open questions
The two materials are not compared in any study cited here, and their evidence bases answer different questions, so the rows are descriptions placed alongside each other rather than a measured contrast. The regulatory rows are the clearest documented difference, but they also mean the two are not substitutable in a regulatory filing or a market-entry plan. Much of the hADM literature concerns sheet forms in reconstructive surgery; the injectable evidence is recent and smaller.